Synergy Pharmaceuticals buy klostergang
Summary
This prediction ended on 07.12.15 with a price of €5.60. The price of Synergy Pharmaceuticals has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.11%. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Synergy Pharmaceuticals | - | - | - | - |
iShares Core DAX® | 1.560% | 2.566% | 18.261% | 16.927% |
iShares Nasdaq 100 | 0.517% | 1.894% | 25.521% | 35.441% |
iShares Nikkei 225® | 1.730% | 5.631% | 18.569% | 13.063% |
iShares S&P 500 | 1.482% | 1.594% | 24.989% | 38.339% |
Comments by klostergang for this prediction
In the thread Synergy Pharmaceuticals diskutieren
Synergy Pharmaceuticals
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.
http://seekingalpha.com/article/3222246-synergy-this-popular-biotech-is-approaching-a-major-clinical-event-heres-how-to-trade-it
Stopped prediction by klostergang for Synergy Pharmaceuticals
Synergy Pharmaceuticals
12.03.18
06.03.19
06.03.19
Synergy Pharmaceuticals
08.09.17
08.03.18
08.03.18